Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effect Of Aspirin On Survival in in Patients Undergoing Chronic Hemodialysis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02261025
Recruitment Status : Completed
First Posted : October 9, 2014
Last Update Posted : October 23, 2014
Sponsor:
Information provided by (Responsible Party):
Hui Min Jin, Shanghai Jiao Tong University School of Medicine

Brief Summary:
The aim of present study is to examine the effect of low-dose aspirin on the incidence of cardiovascular events and mortality in patients undergoing chronic hemodialysis.

Condition or disease Intervention/treatment Phase
Hemodialysis Drug: acetylsalicylic acid Not Applicable

Detailed Description:
This study prospectively evaluate the impacts of low dose aspirin on survival and cardio-cerebral vascular events in a large cohort of Chinese patients undergoing chronic hemodialysis. Between January 2008, consecutive patients with hemodialysis with aspirin were enrolled.We examine the association of aspirin with all-cause mortality in patients matched by propensity scores using the Kaplan-Meier method and Cox models in "intention-to-treat" analyses.The secondary endpoint was rate of cardio-cerebral events.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 410 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: The Effect Of Aspirin On Survival in in Patients Undergoing Chronic Hemodialysis
Study Start Date : January 2008
Actual Primary Completion Date : September 2014
Actual Study Completion Date : September 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Dialysis
Drug Information available for: Aspirin

Arm Intervention/treatment
Experimental: Aspirin group
Aspirin 75-100mg,per day,oral
Drug: acetylsalicylic acid
75-100mg,per day
Other Name: Aspirin

No Intervention: non-aspirin group
No interventions



Primary Outcome Measures :
  1. survival rate [ Time Frame: 5 years ]

Secondary Outcome Measures :
  1. cardio-cerebral event [ Time Frame: 5 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

All patients aged 18 to 85, undergoing chronic hemodialysis, who have none of the following exclusion criteria.

Exclusion Criteria:

History of gastric or duodenal ulcers Known allergy to aspirin or other NSAIDs


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Hui Min Jin, Shanghai Jiao Tong University School of Medicine
ClinicalTrials.gov Identifier: NCT02261025     History of Changes
Other Study ID Numbers: 20120308
First Posted: October 9, 2014    Key Record Dates
Last Update Posted: October 23, 2014
Last Verified: October 2014

Keywords provided by Hui Min Jin, Shanghai Jiao Tong University School of Medicine:
aspirin

Additional relevant MeSH terms:
Layout table for MeSH terms
Aspirin
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Antipyretics